Heme arginate (or haem arginate) is a compound of heme and arginine used in the treatment of acute porphyrias.[1][2] This heme product is only available outside the United States and is equivalent to hematin.[3]
| Identifiers | |
|---|---|
| MeSH | Heme+arginate |
PubChem CID
|
|
| UNII | |
| Properties | |
| C40H48FeN8O6+2 | |
| Molar mass | 792.704 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Heme arginate is a heme compound, whereby L-arginine is added to prevent rapid degradation. It is given intravenously, and its action of mechanism is to reduce the overproduction of δ-aminolevulinic acid, which can cause the acute symptoms in an attack of the acute porphyrias.[4]
See also
editReferences
edit- ^ "HAEM ARGINATE FOR THE ACUTE ATTACK OF PORPHYRIA". Porphyria South Africa. Archived from the original on 2012-03-05.
- ^ "Treatment of the Acute Attack". European Porphyria Network. Archived from the original on 5 October 2011. Retrieved 28 August 2011.
- ^ "Panhematin for Acute Porphyria". American Porphyria Foundation. Archived from the original on 12 March 2018. Retrieved 8 July 2016.
- ^ Volin, L; V Rasi; E Vahtera; R Tenhunen (1988). "Heme arginate: effects on hemostasis" (PDF). Blood. 71 (3): 625–628. doi:10.1182/blood.V71.3.625.625. PMID 3345341. Retrieved 28 August 2011.